{"organizations": [], "uuid": "00591ba1b6ece6b6b0b999d69f6db57fea4a2105", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/07/14/johnsonjohnson-results-idUSL4N0ZU44S20150714", "country": "US", "title": "UPDATE 1-J&J profit beats Street; raises full-year forecast", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "UPDATE 1-J&J profit beats Street; raises full-year forecast | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-07-14T16:41:00.000+03:00", "replies_count": 0, "uuid": "00591ba1b6ece6b6b0b999d69f6db57fea4a2105"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/07/14/johnsonjohnson-results-idUSL4N0ZU44S20150714", "ord_in_thread": 0, "title": "UPDATE 1-J&J profit beats Street; raises full-year forecast", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds details, background)\nJuly 14 (Reuters) - Johnson & Johnson reported a better-than-expected profit as sales of its older drugs helped to offset the impact of a strong dollar on revenue from outside the United States.\nThe company raised its profit forecast for the full year on Tuesday, citing strong underlying business growth.\nThe healthcare conglomerate raised its profit forecast to $6.10-$6.20 per share, from $6.04-$6.19. The company cut its profit forecast in April blaming the strong dollar.\nExcluding the impact of the strong dollar, international sales would have grown marginally, the company said.\nThe company's net profit rose to $4.52 billion, or $1.61 per share, in the second quarter, from $4.33 billion, or $1.51 per share, a year earlier.\nExcluding special items, the company earned $1.71 per share.\nRevenue fell nearly 9 percent to $17.79 billion.\nSales of Olysio, the company's hepatitis C treatment, fell nearly 70 percent to $264 million. The drug accounted for 7 percent of revenue last year.\nAnalysts on average had expected a profit of $1.67 per share on revenue of $17.75 billion, according to Thomson Reuters I/B/E/S.\nSales of the company's medical devices fell 12.2 percent to $6.36 billion.\nUp to Monday's close, the stock had fallen 4 percent so far this year, compared with a 2 percent rise in the S&P 500 Index . (Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)", "external_links": [], "published": "2015-07-14T16:41:00.000+03:00", "crawled": "2015-07-14T15:59:59.000+03:00", "highlightTitle": ""}